2017
DOI: 10.1038/ncomms15264
|View full text |Cite
|
Sign up to set email alerts
|

Cis-perturbation of cancer drivers by the HTLV-1/BLV proviruses is an early determinant of leukemogenesis

Abstract: Human T-cell leukaemia virus type-1 (HTLV-1) and bovine leukaemia virus (BLV) infect T- and B-lymphocytes, respectively, provoking a polyclonal expansion that will evolve into an aggressive monoclonal leukaemia in ∼5% of individuals following a protracted latency period. It is generally assumed that early oncogenic changes are largely dependent on virus-encoded products, especially TAX and HBZ, while progression to acute leukaemia/lymphoma involves somatic mutations, yet that both are independent of proviral i… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

10
120
0
5

Year Published

2017
2017
2022
2022

Publication Types

Select...
7
1

Relationship

2
6

Authors

Journals

citations
Cited by 82 publications
(135 citation statements)
references
References 68 publications
10
120
0
5
Order By: Relevance
“…To discriminate between these two hypotheses, we used an improved high-throughput sequencing (HTS) method to simultaneously map proviral integration sites and measure the abundance of the corresponding clones40.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…To discriminate between these two hypotheses, we used an improved high-throughput sequencing (HTS) method to simultaneously map proviral integration sites and measure the abundance of the corresponding clones40.…”
Section: Resultsmentioning
confidence: 99%
“…Given the low PVLs observed in MK886-treated animals, we applied an improved HTS method, which includes several critical modifications in library preparation, and increases the sensitivity of the assay40.…”
Section: Discussionmentioning
confidence: 99%
“…115 However, no proof of concept has been shown, nor has preliminary data been published concerning the identity of the provirus mutated/deleted genes, the immune protection conferred to the vaccinated animals in the long term, the safety assessment of the vaccine, and the proposed strategy to be used to differentiate vaccinated from infected animals. The recent evidence on the role of viral miRNA in BLV pathogenesis 14 together with the finding that BLV proviruses are integrated near cancer drivers, whose expression is perturbed by the integrated proviruses, 16 further emphasizes the need of caution on retroviral live-attenuated vaccines. It should also be borne in mind that the use of an attenuated retroviral vaccine implies a risk for disruption of genes upon insertion into the cellular genome, preventing their expression, and there is also the risk of reversion to virulent, oncogenic forms in the long run.…”
Section: -101mentioning
confidence: 99%
“…Integration sites and PVL were determined as previously described in Rosewick et al 2017 4 and Artesi et al 2017 14 .…”
Section: Identification Of Proviral Integration Sites (Illumina) Andmentioning
confidence: 99%
“…Methods based on ligation mediated PCR and Illumina sequencing have facilitated the identification of hundreds of thousands of insertion sites in exogenous viruses such as Human T-cell leukemia virus-1 (HTLV-1) 2 and Human immunodeficiency virus (HIV-1) 3 . These techniques have shown that in HTLV-1 2 , Bovine Leukemia Virus (BLV) 4 , Avian Leukosis Virus (ALV) 5 and HIV-1 6 integration sites are not random, most likely reflecting clonal selection. In HIV-1 it has also become apparent that provirus integration can drive clonal expansion 3 and contribute to the HIV-1 reservoir, placing a major road block in the way of a complete cure.…”
Section: Introductionmentioning
confidence: 99%